Paola Molinari

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6441031/publications.pdf

Version: 2024-02-01

28	771	516561 16	526166 27
papers	citations	h-index	g-index

28	28	28	1188
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Pharmacology of Kappa Opioid Receptors: Novel Assays and Ligands. Frontiers in Pharmacology, 2022, 13, 873082.	1.6	3
2	Vasopressin receptor 2 mutations in the nephrogenic syndrome of inappropriate antidiuresis show different mechanisms of constitutive activation for G protein coupled receptors. Scientific Reports, 2020, 10, 9111.	1.6	5
3	Megalencephalic Leukoencephalopathy with Subcortical Cysts Disease-Linked MLC1 Protein Favors Gap-Junction Intercellular Communication by Regulating Connexin 43 Trafficking in Astrocytes. Cells, 2020, 9, 1425.	1.8	18
4	Intermittent Î²-adrenergic blockade downregulates the gene expression of Î²-myosin heavy chain in the mouse heart. European Journal of Pharmacology, 2020, 882, 173287.	1.7	5
5	Î²-blockers Reverse Agonist-Induced Î²2-AR Downregulation Regardless of Their Signaling Profile. International Journal of Molecular Sciences, 2020, 21, 512.	1.8	6
6	Megalencephalic Leukoencephalopathy with Subcortical Cysts Protein-1 (MLC1) Counteracts Astrocyte Activation in Response to Inflammatory Signals. Molecular Neurobiology, 2019, 56, 8237-8254.	1.9	19
7	Multivalent ligands for the serotonin 5-HT₄ receptor. MedChemComm, 2017, 8, 647-651.	3.5	4
8	Gain-of-function defects of astrocytic Kir4.1 channels in children with autism spectrum disorders and epilepsy. Scientific Reports, 2016, 6, 34325.	1.6	56
9	Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo). PLoS ONE, 2016, 11, e0156897.	1.1	26
10	Genetically induced dysfunctions of Kir2.1 channels: implications for short QT3 syndrome and autismâ€“epilepsy phenotype. Human Molecular Genetics, 2014, 23, 4875-4886.	1.4	65
11	Synthesis and structureâ€“activity relationship studies in serotonin 5-HT4 receptor ligands based on a benzo[de][2,6]naphthridine scaffold. European Journal of Medicinal Chemistry, 2014, 82, 36-46.	2.6	15
12	Megalencephalic leukoencephalopathy with subcortical cysts protein-1 modulates endosomal pH and protein trafficking in astrocytes: Relevance to MLC disease pathogenesis. Neurobiology of Disease, 2014, 66, 1-18.	2.1	20
13	Ligands Raise the Constraint That Limits Constitutive Activation in G Protein-coupled Opioid Receptors. Journal of Biological Chemistry, 2013, 288, 23964-23978.	1.6	22
14	Megalencephalic leukoencephalopathy with subcortical cysts protein 1 functionally cooperates with the TRPV4 cation channel to activate the response of astrocytes to osmotic stress: dysregulation by pathological mutations. Human Molecular Genetics, 2012, 21, 2166-2180.	1.4	65
15	New red-shifted coelenterazine analogues with an extended electronic conjugation. Tetrahedron Letters, 2012, 53, 5114-5118.	0.7	27
16	Divergent agonist selectivity in activating Î²1- and Î²2-adrenoceptors for G-protein and arrestin coupling. Biochemical Journal, 2011, 438, 191-202.	1.7	28
17	Propranolol enhances cell cycle-related gene expression in pressure overloaded hearts. British Journal of Pharmacology, 2011, 164, 1917-1928.	2.7	10
18	MLC1 trafficking and membrane expression in astrocytes: Role of caveolin-1 and phosphorylation. Neurobiology of Disease, 2010, 37, 581-595.	2.1	30

#	Article	IF	Citations
19	Morphine-like Opiates Selectively Antagonize Receptor-Arrestin Interactions. Journal of Biological Chemistry, 2010, 285, 12522-12535.	1.6	93
20	Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein GÎ±qi5. Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 379, 599-607.	1.4	59
21	Delayed internalization and lack of recycling in a beta2-adrenergic receptor fused to the G protein alpha-subunit. BMC Cell Biology, 2008, 9, 56.	3.0	15
22	Functional complementation of high-efficiency resonance energy transfer: a new tool for the study of protein binding interactions in living cells. Biochemical Journal, 2008, 409, 251-261.	1.7	54
23	Different Structural Requirements for the Constitutive and the Agonist-induced Activities of the Î²2-Adrenergic Receptor. Journal of Biological Chemistry, 2005, 280, 23464-23474.	1.6	13
24	Guanine Nucleotide Exchange-Independent Activation of Gs Protein by Î²2-Adrenoceptor. Molecular Pharmacology, 2005, 68, 720-728.	1.0	12
25	â€œInduced-Fitâ€•Mechanism for Catecholamine Binding to the Î²2-Adrenergic Receptor. Molecular Pharmacology, 2004, 66, 356-363.	1.0	33
26	Expression of OP4 (ORL1, NOP1) receptors in vascular endothelium. European Journal of Pharmacology, 2003, 482, 17-23.	1.7	21
27	Different mechanisms of negative efficacy. Distinguishing inverse agonists from negative antagonists. International Congress Series, 2003, 1249, 1-13.	0.2	1
28	Promiscuous Coupling at Receptor-GÎ± Fusion Proteins. Journal of Biological Chemistry, 2003, 278, 15778-15788.	1.6	46